CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / AZN (AZN) / darolutamide
Forward catalyst · AZN

darolutamide

Sponsor AZN · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

darolutamide is a clinical-stage drug asset sponsored by AZN, listed as AZN. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT03903835. The asset is in Phase 3 and currently recruiting, studied in Metastatic Castration-resistant Prostate Cancer (mCRPC). It appears across 12 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT03903835
PhasePHASE3
StatusRECRUITING
Lead sponsorKarolinska Institutet
Listed asAZN
Condition(s)Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

All tracked catalysts for darolutamide

DateEventConfidenceTrial
2026-12-31READOUTmediumNCT03903835
2027-07-30READOUTmediumNCT05794906
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More AZN catalysts